Neuroscience News and Research

RSS

Integra LifeSciences VP honored as Fellow of the American Academy of Nursing

Integra LifeSciences Holdings Corporation announced today that Linda Littlejohns RN MSN CCRN CNRN, Vice President, Clinical Development at Integra, has been selected as a Fellow of the American Academy of Nursing, one of the most prestigious nursing organizations in the country. The Academy's Fellows include many of the nation's top nursing executives, policymakers, scholars, researchers and practitioners.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

US District Court upholds validity and enforceability of CRESTOR patent

AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

30 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

Researchers study mechanism of human brain

Because of its intricate organization, figuring out the wiring diagram that explains how the billions of neurons in the brain are connected, and determining how they work together, remains a formidable task.

29 Jun 2010

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Astellas Pharma Inc. announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine.

29 Jun 2010

Researchers use neonatal piglet model to study infant brain development

Events occurring during the development of an infant's brain can leave behind fingerprints. And researchers at the University of Illinois are interested in learning how these fingerprints can predict future behavioral problems such as cognitive deficits, anxiety disorders, depression, and even autism.

29 Jun 2010

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Anesthesia & Analgesia (A&A), official journal of the International Anesthesia Research Society (IARS), has achieved a significant increase in its Impact Factor, a key indicator of the influence and scientific value of medical journals, the IARS announced today.

29 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

The U.S. Department of Defense and the Intrepid Fallen Heroes Fund on June 24 officially dedicated the National Intrepid Center of Excellence, a new 72,000-square-foot medical facility in Bethesda, Md., dedicated to researching, diagnosing and treating traumatic brain injury in U.S. military personnel.

28 Jun 2010

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, Inc. and its collaborators, including the Center for Stem Cell and Regenerative Medicine and Case Western Reserve University, announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support research into the treatment of spinal cord injury with MultiStem, Athersys' proprietary stem cell product candidate.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Brain scanning study has implications for advertising and public health campaigns

In a study with implications for the advertising industry and public health organizations, UCLA neuroscientists have shown they can use brain scanning to predict whether people will use sunscreen during a one-week period even better than the people themselves can.

25 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

Group of tests may help predict falls in people with Parkinson's disease: Study

A group of tests may help predict which people with Parkinson's disease are more likely to fall, according to a study published in the June 23, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

24 Jun 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

Researchers study why the brain of newborn baby is particularly flexible

Science has long puzzled over why a baby's brain is particularly flexible and why it easily changes. Is it because babies have to learn a lot? A group of researchers from the Bernstein Network Computational Neuroscience, the Max Planck Institute for Dynamics and Self-Organization in G-ttingen, the Schiller University in Jena and Princeton University have now put forward a new explanation: Maybe it is because the brain still has to grow.

23 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

UCL scientists explain Parkinson's disease patients' ICBs

Scientists at UCL have explained Parkinson's patients' risky behaviour, a rare side effect of standard treatments for the disease. The finding has implications for future medication of patients.

23 Jun 2010

Neuroscience News and Research

Integra LifeSciences VP honored as Fellow of the American Academy of Nursing

Study highlights importance of individualized, patient-centered therapies

US District Court upholds validity and enforceability of CRESTOR patent

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Researchers study mechanism of human brain

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Researchers use neonatal piglet model to study infant brain development

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Brain scanning study has implications for advertising and public health campaigns

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Group of tests may help predict falls in people with Parkinson's disease: Study

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

Researchers study why the brain of newborn baby is particularly flexible

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

UCL scientists explain Parkinson's disease patients' ICBs

Neuroscience - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News